Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

...And with FDA

Executive Summary

Former Center for Drug Evaluation & Research Office of Antimicrobial Products Director Mark Goldberger is appointed to the newly created position of Emergency & Pandemic Threat Preparedness Medical Director in the Center for Biologics Evaluation & Research, where he will guide development and evaluation of products related to pandemic threats...

You may also be interested in...



Antimicrobial office acting director

CDER Office of Antimicrobial Drug Products Deputy Director Edward Cox is named acting director effective Aug. 21. Former director Mark Goldberger recently accepted a position in CBER as medical director for emerging and pandemic threat preparedness effective Aug. 20 (1"The Pink Sheet" July 24, 2006, In Brief). Division of Antiviral Drug Products Deputy Director Jeff Murray will serve as acting deputy director of OAP...

US House Co-signs Banking For Hemp Industry

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials

Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.

UsernamePublicRestriction

Register

PS047399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel